IL276200B2 - Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease - Google Patents

Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease

Info

Publication number
IL276200B2
IL276200B2 IL276200A IL27620020A IL276200B2 IL 276200 B2 IL276200 B2 IL 276200B2 IL 276200 A IL276200 A IL 276200A IL 27620020 A IL27620020 A IL 27620020A IL 276200 B2 IL276200 B2 IL 276200B2
Authority
IL
Israel
Prior art keywords
vwf
polypeptide
human
ttp
related disease
Prior art date
Application number
IL276200A
Other languages
English (en)
Hebrew (he)
Other versions
IL276200B1 (en
IL276200A (en
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of IL276200A publication Critical patent/IL276200A/en
Publication of IL276200B1 publication Critical patent/IL276200B1/en
Publication of IL276200B2 publication Critical patent/IL276200B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL276200A 2018-02-06 2019-02-06 Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease IL276200B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627082P 2018-02-06 2018-02-06
US201862662381P 2018-04-25 2018-04-25
PCT/EP2019/052929 WO2019154867A1 (en) 2018-02-06 2019-02-06 Methods of treating initial episode of ttp with immunoglobulin single variable domains

Publications (3)

Publication Number Publication Date
IL276200A IL276200A (en) 2020-09-30
IL276200B1 IL276200B1 (en) 2024-09-01
IL276200B2 true IL276200B2 (en) 2025-01-01

Family

ID=65440943

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276200A IL276200B2 (en) 2018-02-06 2019-02-06 Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease

Country Status (15)

Country Link
US (1) US11999797B2 (https=)
EP (1) EP3749696A1 (https=)
JP (2) JP2021512947A (https=)
KR (1) KR102929403B1 (https=)
CN (1) CN111670202A (https=)
AU (1) AU2019217584B2 (https=)
BR (1) BR112020015991A2 (https=)
CA (1) CA3089211A1 (https=)
IL (1) IL276200B2 (https=)
MX (1) MX2020008294A (https=)
MY (1) MY204220A (https=)
SG (1) SG11202006902QA (https=)
TW (1) TWI889647B (https=)
WO (1) WO2019154867A1 (https=)
ZA (1) ZA202004370B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193326A1 (en) * 2014-06-16 2015-12-23 Ablynx Nv Methods of treating ttp with immunoglobulin single variable domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
NZ576284A (en) 2003-01-10 2010-07-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193326A1 (en) * 2014-06-16 2015-12-23 Ablynx Nv Methods of treating ttp with immunoglobulin single variable domains and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F. PEYVANDI ET AL,, CAPLACIZUMAB REDUCES THE FREQUENCY OF MAJOR THROMBOEMBOLIC EVENTS, EXACERBATIONS AND DEATH IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA, 5 June 2017 (2017-06-05) *
FLORA PEYVANDI ET AL,, CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA, 11 February 2016 (2016-02-11) *
MARIE SCULLY ET AL,, RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 HERCULES STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA, 1 December 2017 (2017-12-01) *

Also Published As

Publication number Publication date
ZA202004370B (en) 2024-08-28
US20210221912A1 (en) 2021-07-22
KR20200118444A (ko) 2020-10-15
BR112020015991A2 (pt) 2020-12-15
JP2021512947A (ja) 2021-05-20
TW201945030A (zh) 2019-12-01
WO2019154867A1 (en) 2019-08-15
RU2020129228A (ru) 2022-03-09
CA3089211A1 (en) 2019-08-15
MY204220A (en) 2024-08-16
CN111670202A (zh) 2020-09-15
SG11202006902QA (en) 2020-08-28
IL276200B1 (en) 2024-09-01
MX2020008294A (es) 2020-11-18
TWI889647B (zh) 2025-07-11
JP2024001135A (ja) 2024-01-09
US11999797B2 (en) 2024-06-04
EP3749696A1 (en) 2020-12-16
KR102929403B1 (ko) 2026-02-24
AU2019217584B2 (en) 2025-08-14
IL276200A (en) 2020-09-30
AU2019217584A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7105260B2 (ja) 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用
JP2024001135A (ja) Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
RU2794143C2 (ru) Способы лечения первоначального эпизода ttp с помощью одиночных вариабельных доменов иммуноглобулинов
HK40078326A (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
HK1256731B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1258508B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
HK1256730B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930A1 (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1236434B (en) Immunoglobulin single variable domains for use in treating ttp